Prolonged response on olaparib maintenance in metastatic pancreatic acinar cell carcinoma associated with a germline BRCA 2 mutation, revealed by severe panniculitis

被引：5
|
作者：
Lelong, Margaux [1 ]
Raoul, Jean-Luc [1 ]
Touchefeu, Yann [2 ]
Berthelot, Jean-Marie [3 ]
Arnolfo, Paul [3 ]
Matysiak-Budnik, Tamara [2 ]
Senellart, Helene [1 ]
机构：
[1] Inst Cancerol Ouest, Dept Med Oncol, Blvd Prof Jacques MONOD, F-44805 St Herblain, France
[2] Univ Hosp, Dept Gastroenterol, IMAD, Nantes, France
[3] Univ Hosp, Dept Rhumatol, Nantes, France
来源：
CLINICAL CASE REPORTS | 2022年 / 10卷 / 12期
关键词：
BRCA mutation; lipase; long survival; pancreatic acinar cell cancer; panniculitis;
D O I：
10.1002/ccr3.6718
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
This 38-year-old man has a familial BRCA2 mutation. He presented with skin erythema, polyarthritis, dactylitis, and febrile erythema nodosum; a biopsy of a liver metastase revealed acinar cell carcinoma of the pancreas. After FOLFIRINOX, olaparib was initiated, and 24 months after, the patient was PS 0 and asymptomatic.
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Extended overall survival results from the POLO study of active maintenance olaparib in patients with metastatic pancreatic cancer and a germline BRCA mutation
    Arnold, Dirk
    Hammel, Pascal
    Golan, Talia
    Reni, Michele
    Van Cutsem, Eric
    Macarulla, Teresa
    Hall, Michael J.
    Park, Joon Oh
    Hochhauser, Daniel
    Oh, Do-Youn
    Reinacher-Schick, Anke
    Tortora, Giampaolo
    Algul, Hana
    O'reilly, Eileen M.
    Sharan, Kanu
    Ou, Xiaoling
    Cui, Karen
    Locker, Gershon Y.
    Kindler, Hedy L.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 91 - 92
  • [22] Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial
    Zhan, Mei
    Zheng, Hanrui
    Yang, Yu
    He, Zhiyao
    Xu, Ting
    Li, Qiu
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 12919 - 12926
  • [23] Extended overall survival results from the POLO study of active maintenance olaparib in patients with metastatic pancreatic cancer and a germline BRCA mutation
    Hammel, P.
    Golan, T.
    Reni, M.
    Van Cutsem, E.
    Macarulla Mercade, T.
    Hall, M.
    Park, J. O.
    Hochhauser, D.
    Arnold, D.
    Oh, D-Y.
    Reinacher-Schick, A.
    Tortora, G.
    Alguel, H.
    O'Reilly, E.
    Sharan, K.
    Ou, X.
    Cui, K. Y.
    Locker, G.
    Kindler, H.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1137 - S1137
  • [24] Pancreatic Panniculitis Associated with Acinar Cell Carcinoma of the Pancreas: A Case Report
    Zheng, Zhen Jiang
    Gong, Jun
    Xiang, Guang Ming
    Mai, Gang
    Liu, Xu Bao
    ANNALS OF DERMATOLOGY, 2011, 23 (02) : 225 - 228
  • [25] Pancreatic mixed acinar-neuroendocrine carcinoma in a patient with a germline BRCA2 mutation: a case report
    Ikeda, Mio
    Miura, Shin
    Kume, Kiyoshi
    Kikuta, Kazuhiro
    Hamada, Shin
    Takikawa, Tetsuya
    Nakagawa, Kei
    Unno, Michiaki
    Furukawa, Toru
    Masamune, Atsushi
    CLINICAL JOURNAL OF GASTROENTEROLOGY, 2022, 15 (05) : 999 - 1005
  • [26] Adverse events (AEs) with maintenance olaparib in patients with a germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer (mPaC): Phase III POLO trial
    Algul, H.
    Reni, M.
    Kindler, H. L.
    Hammel, P.
    Van Cutsem, E.
    Macarulla, T.
    Hall, M. J.
    Park, J. O.
    Hochhauser, D.
    Arnold, D.
    Oh, D-Y
    Reinacher-Schick, A.
    Tortora, G.
    O'Reilly, E.
    McGuiness, D.
    Cui, K.
    Schlienger, K.
    Locker, G.
    Golan, T.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 216 - 216
  • [27] POLO: Time to treatment discontinuation and subsequent therapies following maintenance olaparib for patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC)
    Van Cutsem, E.
    Golan, T.
    Hammel, P.
    Reni, M.
    Macarulla, T.
    Hall, M. J.
    Park, J. O.
    Hochhauser, D.
    Arnold, D.
    Oh, D-Y.
    Reinacher-Schick, A.
    Tortora, G.
    Alguel, H.
    O'Reilly, E. M.
    McGuinness, D.
    Cui, K. Y.
    Schlienger, K.
    Locker, G. Y.
    Kindler, H. L.
    ANNALS OF ONCOLOGY, 2019, 30 : 264 - +
  • [28] Extended Overall Survival Results from the POLO Study of active Maintenance Therapy with Olaparib in Patients with metastatic Pancreatic Cancer and a Germline BRCA Mutation
    Arnold, D.
    Golan, T.
    Hammel, P.
    Reni, M.
    Van Cutsem, E.
    Macarulla, T.
    Hall, J. M.
    Park, Oh J.
    Hochhauser, D.
    Oh, D. -Y.
    Reinacher-Schick, A.
    Tortora, G.
    Alguel, H.
    O'Reilly, M. E.
    Kindler, L. H.
    Sharan, K.
    Ou, X.
    Cui, K.
    Locker, Y. G.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 224 - 225
  • [29] Adverse events (AEs) with maintenance olaparib in patients with a germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer (mPaC): Phase III POLO trial
    Reni, Michele
    Kindler, Hedy L.
    Hammel, Pascal
    Van Cutsem, Eric
    Macarulla, Teresa
    Hall, Michael J.
    Park, Joon Oh
    Hochhauser, Daniel
    Arnold, Dirk
    Oh, Do-Youn
    Reinacher-Schick, Anke C.
    Tortora, Giampaolo
    Algul, Hana
    O'Reilly, Eileen Mary
    McGuinness, David
    Cui, Karen
    Schlienger, Katia
    Locker, Gershon Y.
    Golani, Talia
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [30] Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC
    Yang, Hong
    Liu, Zhimin
    Wang, Yufang
    Li, Jun
    Li, Ruiqian
    Wang, Qilin
    Hu, Chen
    Jiang, Haiyang
    Wu, Hongyi
    Song, Lele
    Bai, Yu
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
12345